Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Arcellx Inc ( (ACLX) ) just unveiled an update.
Arcellx Inc. held its Annual Meeting of Stockholders on May 28, 2025, where approximately 96.15% of the outstanding shares were represented. During the meeting, three Class III directors were elected, the executive compensation was approved on an advisory basis, and the appointment of PricewaterhouseCoopers LLP as the independent registered accounting firm for the fiscal year ending December 31, 2025, was ratified.
The most recent analyst rating on (ACLX) stock is a Buy with a $85.00 price target. To see the full list of analyst forecasts on Arcellx Inc stock, see the ACLX Stock Forecast page.
Spark’s Take on ACLX Stock
According to Spark, TipRanks’ AI Analyst, ACLX is a Neutral.
Arcellx Inc’s stock score reflects a mix of financial challenges and promising corporate developments. While financial performance and valuation are pressured by ongoing losses, positive clinical trial results and strategic board changes offer potential upside. Technical signals suggest a neutral market sentiment.
To see Spark’s full report on ACLX stock, click here.
More about Arcellx Inc
Average Trading Volume: 799,273
Technical Sentiment Signal: Sell
Current Market Cap: $3.41B
See more data about ACLX stock on TipRanks’ Stock Analysis page.